Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alogliptin Benzoate

FDA-approved product (tablet, oral), marketed as Nesina.

Registered studies
10
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Alogliptin Benzoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alogliptin Benzoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alogliptin Benzoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers

    NCT05364164 · start 2022-07-09

    Registered record
    Registry ID
    NCT05364164
    Conditions
    Healthy
    Interventions
    CT-L01 12.5/1,000 mg; CT-L01 12.5/1,000 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-09
    Completion
    2022-07-25
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCT-L01 12.5/1,000 mg; CT-L01 12.5/1,000 mg
    PhasePhase 1
    Registry statusCompleted

  • A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers

    NCT05363592 · start 2022-06-25

    Registered record
    Registry ID
    NCT05363592
    Conditions
    Healthy
    Interventions
    CT-L01 12.5/500 mg; Alogliptin Benzoate 12.5 mg; Metformin HCl XR 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-25
    Completion
    2022-07-25
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCT-L01 12.5/500 mg; Alogliptin Benzoate 12.5 mg; Metformin HCl XR 500 mg
    PhasePhase 1
    Registry statusCompleted

  • A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers

    NCT05363384 · start 2022-06-11

    Registered record
    Registry ID
    NCT05363384
    Conditions
    Healthy
    Interventions
    CT-L01; Alogliptin Benzoate 25 mg; Metformin HCl XR 1,000 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-11
    Completion
    2022-07-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCT-L01; Alogliptin Benzoate 25 mg; Metformin HCl XR 1,000 mg
    PhasePhase 1
    Registry statusCompleted

  • Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    NCT05220917 · start 2021-08-01

    Registered record
    Registry ID
    NCT05220917
    Conditions
    Cardiovascular Events; Type2 Diabetes; Renal Disease
    Interventions
    SGLT2 inhibitor; DPP-4 inhibitor; GLP-1RA; 2nd generation SU
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-08-01
    Completion
    2027-09-30
    Enrolment
    781,430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Events; Type2 Diabetes; Renal Disease
    InterventionSGLT2 inhibitor; DPP-4 inhibitor; GLP-1RA; 2nd generation SU
    PhaseNot recorded
    Registry statusActive not recruiting

  • To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes

    NCT03950505 · start 2020-05-29

    Registered record
    Registry ID
    NCT03950505
    Conditions
    Non-alcoholic Steatohepatitis; Type2 Diabetes
    Interventions
    Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-05-29
    Completion
    2020-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-alcoholic Steatohepatitis; Type2 Diabetes
    InterventionNesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
    PhasePhase 4
    Registry statusUnknown

  • Phase 3 Alogliptin Pediatric Study

    NCT02856113 · start 2016-10-14

    Registered record
    Registry ID
    NCT02856113
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Alogliptin Benzoate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-10-14
    Completion
    2022-02-14
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionAlogliptin Benzoate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2

    NCT02756832 · start 2016-09-20

    Registered record
    Registry ID
    NCT02756832
    Conditions
    Diabetes Mellitus
    Interventions
    Alogliptin Benzoate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-09-20
    Completion
    2018-04-28
    Enrolment
    1,409

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionAlogliptin Benzoate
    PhaseNot recorded
    Registry statusCompleted

  • A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea

    NCT04980014 · start 2015-10-02

    Registered record
    Registry ID
    NCT04980014
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    NesinaAct® Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-10-02
    Completion
    2019-08-30
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionNesinaAct® Tablet
    PhaseNot recorded
    Registry statusCompleted

  • The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

    NCT02798172 · start 2014-05

    Registered record
    Registry ID
    NCT02798172
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Alogliptin and Metformin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2015-08
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionAlogliptin and Metformin
    PhaseNot applicable
    Registry statusCompleted

  • A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

    NCT04980040 · start 2014-04-19

    Registered record
    Registry ID
    NCT04980040
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Alogliptin Benzoate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-04-19
    Completion
    2019-08-30
    Enrolment
    3,623

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionAlogliptin Benzoate
    PhaseNot recorded
    Registry statusCompleted